Mr. George Achilleos reports

NETRAMARK ANNOUNCES UPLISTING TO TORONTO STOCK EXCHANGE

Netramark Holdings Inc. will be uplisting to the Toronto Stock Exchange (the TSX). The common shares of the company will be voluntarily delisted from the Canadian Securities Exchange (the CSE) effective as of close of market on Feb. 17, 2026, and will commence trading on the TSX effective at market open on Feb. 18, 2026, under its current stock symbol AIAI.

The company will remain a reporting issuer under applicable Canadian securities laws through the listing transition process from the CSE to the TSX. The common shares will continue to be listed on the OTCQB under the symbol AINMF and the Frankfurt Stock Exchange under the symbol PF0. Shareholders are not required to take any action in connection with the TSX uplisting.

The company believes that listing on the TSX reflects Netramark's continued operational development and strengthens its positioning within the capital markets as it advances commercial adoption of NetraAI.

"Uplisting to the TSX is a significant milestone that we believe will enhance our access to institutional investors and raise our profile in the capital markets as we focus on accelerating the growth of NetraAI, our AI-powered precision-analytics technology platform for the pharmaceutical industry," said George Achilleos, chief executive officer of Netramark. "Over the past several years, we have concentrated on advancing our technology, strengthening our governance framework, and expanding engagement with pharmaceutical sponsors and clinical research organizations. We believe the TSX listing appropriately reflects that progress."

About NetraAI

In contrast to other artificial-intelligence-based methods, NetraAI is uniquely engineered to include focus mechanisms that separate small data sets into explainable and unexplainable subsets. Unexplainable subsets are collections of patients that can lead to suboptimal overfit models and inaccurate insights due to poor correlations with the variables involved. NetraAI uses explainable subsets to derive insights and hypotheses (including factors that influence treatment and placebo responses and adverse events), potentially increasing the likelihood of a clinical trial's success. Many other AI methods lack these focus mechanisms and assign every patient to a class, often leading to overfitting, which drowns out critical information that could have been used to improve a trial's chance of success.

About Netramark Holdings Inc.

Netramark is focused on being a leader in the development of generative artificial intelligence (Gen AI)/machine learning (ML) solutions targeted at the pharmaceutical industry. Its product offering uses a novel topology-based algorithm that can parse patient data sets into subsets of people that are strongly related according to several variables simultaneously. This allows Netramark to use a variety of ML methods, depending on the character and size of the data, to transform the data into powerfully intelligent information that activates traditional AI/ML methods. The result is that Netramark can work with much smaller data sets and accurately segment diseases into different types, as well as accurately classify patients for sensitivity to drugs and/or efficacy of treatment.

We seek Safe Harbor.